How the Phase 3 Trial Assessing an Investigational Dose of Semaglutide Injection for Type 2 Diabetes Was Conducted

Video

Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses how the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide injection in adults with type 2 diabetes was conducted.

Pharmacy Times interviewed Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, on results from the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide (Ozempic; Novo Nordisk) injection in adults with type 2 diabetes.

During the discussion, Radin addresses how the phase 3 SUSTAIN FORTE trial was conducted.

Related Videos
Woman Physician Talking With Her Patient | Image Credit: LStockStudio - stock.adobe.com
A health visitor explaining a senior woman how to take pills - Image credit: Halfpoint | stock.adobe.com
Diabetes patient turn knob on end of insulin pen and dial up correct insulin dose for injection. Scale window on pen syringe showing number of units dose. Medical equipment is easy to self injection - Image credit: Orawan | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image credit: Andrea Izzotti
Inflation Reduction Act is shown using the text and the US flag - Image credit: Andrii | stock.adobe.com
3D illustration of heart
Model of a heart
Man experiencing heart pain
© 2023 MJH Life Sciences

All rights reserved.